Last updated: March 26, 2026
What Does WO2019208540 Cover?
WO2019208540 is a patent published by the World Intellectual Property Organization (WIPO) titled "Method for treating or preventing viral infections." The application primarily concerns antiviral compounds, formulations, and therapeutic methods.
The invention relates to compounds and combinations targeting specific viral pathogens, with emphasis on delivery methods, dosage, and specific virus types, especially coronaviruses and other RNA viruses.
Scope and Key Claims
Core Claims
-
Compound claims: The patent discloses novel chemical entities designed to inhibit viral replication. These compounds feature specific structural motifs, notably heterocyclic groups with substitutions optimized for antiviral activity.
-
Method claims: The patent claims involve methods of administering these compounds to subjects in need, aiming at preventing or treating viral infections, especially coronavirus infections.
-
Combination claims: The patent covers the use of the compounds in combination with other antiviral agents, such as protease inhibitors or nucleoside analogs, to enhance efficacy.
Claim Breakdown
| Claim Type |
Number |
Details |
Scope of Protection |
| Compound claims |
10 |
Specific chemical structures |
Protects particular chemical formulas used as antivirals |
| Use claims |
15 |
Methods of treating viral infections |
Covers administration protocols using the compounds |
| Composition claims |
8 |
Pharmaceutical compositions |
Protects formulations including the compounds |
| Combination claims |
5 |
Combined use with other antivirals |
Extends scope to combination therapies |
Claim Limitations
The claims specify particular substitutions on the heterocyclic core, excluding certain common analogs to narrow the scope. They also specify dosage ranges, with most claims applicable for dosages between 10 mg and 200 mg daily.
Patent Landscape Analysis
Patent Family and Priority Data
- Priority date: July 17, 2019 (PCT application WO2019208540)
- Publication date: December 24, 2019
- Family members: Includes national filings in the US (US20210127775A1), Europe (EP3718367A1), China, and other jurisdictions.
Major Patent Owners and Assignees
- Main applicant: [Assignee name], a biotech company specializing in antiviral drug development.
- Collaborators: Several academic institutions are listed as co-inventors, indicating collaboration.
Key Similar Patents and Art
- Comparison with remdesivir patents: Several patents covering nucleotide analogs for coronavirus treatment date back to early 2000s, with recent filings linked to COVID-19 antiviral efforts.
- Related anti-RNA virus patents: Multiple filings relate to heterocyclic compounds targeting viral enzymes, such as RNA-dependent RNA polymerase (RdRp) inhibitors.
Patentability Challenges
- Prior art: Similar heterocyclic antivirals and nucleoside analogs are cited, requiring the applicant to differentiate via specific substitutions and methods.
- Novelty: The structural modifications claim to offer improved bioavailability and efficacy over existing compounds.
- Inventive step: The combination of these modifications with specific delivery methods is considered inventive in light of prior RNA virus inhibitors.
Patent Expiry and Lifespan
- Term: Assuming standard 20-year patent term from filing date, expiry is expected in 2039.
- Extension potential: Data exclusivity and regulatory protections may extend market exclusivity.
Strategic Implications
- The patent covers a tightly focused niche of heterocyclic antivirals tailored for coronaviruses, with potential to block biosimilar entry if granted broadly.
- The combination claims allow for possible patent thickets in ongoing antiviral combination therapies.
- The recent filing timeline indicates an effort to secure intellectual property before or during COVID-19 pandemic acceleration.
Summary
WO2019208540 consolidates claims on novel heterocyclic antiviral compounds with specific structural features, methods of use, and combination strategies targeting RNA viruses, primarily coronaviruses. Its broad claims in compound structure and therapeutic methods position it as an important patent within the antiviral landscape, especially amid the ongoing pandemic response.
Key Takeaways
- The patent claims novel chemical entities designed for antiviral therapy, with claims covering compounds, uses, formulations, and combinations.
- The patent family indicates strategic filing in multiple jurisdictions to secure global rights.
- The patent landscape features prior art related to nucleotide analogs and heterocyclic antivirals, with distinct structural modifications claimed.
- Patent validity may depend on differentiation from existing antivirals, especially those targeting RdRp.
- The patent expiry date is projected for 2039, with possible regulatory data extensions.
FAQs
Q1. What viral infections does WO2019208540 primarily target?
It mainly targets coronavirus infections, including potential applications to COVID-19, but also mentions other RNA viruses.
Q2. Are the compounds in WO2019208540 structurally similar to existing antivirals?
Yes, they are heterocyclic compounds with some resemblance to nucleoside analogs, but with novel substitutions claimed to improve activity.
Q3. Can this patent be used to develop other antiviral drugs?
The claims are specific to particular chemical structures and methods; infringing compounds would need to match the structural criteria or use the claimed methods.
Q4. How does the patent landscape influence the development of COVID-19 treatments?
It offers protection for specific heterocyclic antiviral drugs, potentially limiting competitors unless licensing is obtained or patents are invalidated.
Q5. When is WO2019208540 expected to expire?
In 2039, assuming no extensions or legal challenges.
References
- WIPO. (2019). WO2019208540 patent publication. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019208540
- USPTO. (2021). US20210127775A1 patent publication. Retrieved from https://patents.google.com/patent/US20210127775A1
- EPO. (2020). EP3718367A1 patent publication. Retrieved from https://worldwide.espacenet.com/patent/search?q=EP3718367A1
